Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants

Background Metabolic-bariatric surgery delivers substantial weight loss and can induce remission or improvement of obesity-related risks and complications. However, more robust estimates of its effect on long-term mortality and life expectancy-especially stratified by pre-existing diabetes status-are needed to guide policy and facilitate patient counselling. We compared long-term survival outcomes of severely obese patients who received metabolic-bariatric surgery versus usual care. Methods We did a prespecified one-stage meta-analysis using patient-level survival data reconstructed from prospective controlled trials and high-quality matched cohort studies. We searched PubMed, Scopus, and MEDLINE (via Ovid) for randomised trials, prospective controlled studies, and matched cohort studies comparing all-cause mortality after metabolic-bariatric surgery versus non-surgical management of obesity published between inception and Feb 3, 2021. We also searched grey literature by reviewing bibliographies of included studies as well as review articles. Shared-frailty (ie, random-effects) and stratified Cox models were fitted to compare all-cause mortality of adults with obesity who underwent metabolic-bariatric surgery compared with matched controls who received usual care, taking into account clustering of participants at the study level. We also computed numbers needed to treat, and extrapolated life expectancy using Gompertz proportional-hazards modelling. The study protocol is prospectively registered on PROSPERO, number CRD42020218472. Findings Among 1470 articles identified, 16 matched cohort studies and one prospective controlled trial were included in the analysis. 7712 deaths occurred during 1.2 million patient-years. In the overall population consisting 174 772 participants, metabolic-bariatric surgery was associated with a reduction in hazard rate of death of 49.2% (95% CI 46.3-51.9, p<0.0001) and median life expectancy was 6.1 years (95% CI 5.2-6.9) longer than usual care. In subgroup analyses, both individuals with (hazard ratio 0.409, 95% CI 0.370-0.453, p<0.0001) or without (0.704, 0.588-0.843, p<0.0001) baseline diabetes who underwent metabolic-bariatric surgery had lower rates of all-cause mortality, but the treatment effect was considerably greater for those with diabetes (between-subgroup I-2 95.7%, p<0.0001). Median life expectancy was 9.3 years (95% CI 7.1-11.8) longer for patients with diabetes in the surgery group than the non-surgical group, whereas the life expectancy gain was 5.1 years (2.0-9.3) for patients without diabetes. The numbers needed to treat to prevent one additional death over a 10-year time frame were 8.4 (95% CI 7.8-9.1) for adults with diabetes and 29.8 (21.2-56.8) for those without diabetes. Treatment effects did not appear to differ between gastric bypass, banding, and sleeve gastrectomy (I-2 3.4%, p=0.36). By leveraging the results of this meta-analysis and other published data, we estimated that every 1.0% increase in metabolic-bariatric surgery utilisation rates among the global pool of metabolic-bariatric candidates with and without diabetes could yield 5.1 million and 6.6 million potential life-years, respectively. Interpretation Among adults with obesity, metabolic-bariatric surgery is associated with substantially lower all-cause mortality rates and longer life expectancy than usual obesity management. Survival benefits are much more pronounced for people with pre-existing diabetes than those without. Copyright (C) 2021 Elsevier Ltd. All rights reserved.